(036) Comparative Analysis of FLAG-Ida +/- Venetoclax vs. CLAG-Ida +/- Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Poster Abstract: Background/Rationale:
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the rapid growth of abnormal myeloid cells in the bone marrow. The induction phase of treatment aims to achieve a complete remission, characterized by the absence of leukemic cells in the bone marrow, thus improving patient outcomes and prognosis. In recent years, several induction chemotherapy regimens have been developed to enhance the effectiveness of treatment for AML. FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) and CLAG-Ida (cladribine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) are two such protocols that have shown efficacy in inducing remission in AML patients. The specific purpose for the comparison is due to the switch from FLAG-Ida to CLAG-Ida during the nationwide Fludarabine shortage. The addition of Venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, to these regimens, has shown promise in improving outcomes in AML patients.

Methods:
In this single-center retrospective study will include newly diagnosed AML patients 18 years or older who received at least one cycle of FLAG-Ida +/- Venetoclax or CLAG-Ida +/- Venetoclax induction at Northside Hospital Atlanta’s Cancer Institute unit between January 1, 2021 and May 31, 2023. This study will analyze the clinical efficacy including complete response rate (CR); safety profile of each regimen including adverse effects, patient stratification based on age, cytogenetic and molecular abnormalities, and comorbidities; and the contribution of Venetoclax to each regimen. This analysis will investigate the significance of drug therapy changes secondary to drug shortage to determine possible long-term effects and outcomes.

Results:
Results pending.

Conclusion:
Discussion of results will be presented at the 2024 HOPA Annual Conference.

References (must also be included in final poster): N/A